[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Sign Up to like & getrecommendations! Published in 2018 at "Der Nervenarzt"
DOI: 10.1007/s00115-018-0498-0
Abstract: BACKGROUND The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS). OBJECTIVE Cladribine tablets (Mavenclad®), an oral RMS medication with an innovative treatment concept, have… read more here.
Keywords: relapsing remitting; treatment; cladribine tablets; disease activity ... See more keywords
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01186-z
Abstract: Introduction Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted. Methods The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the… read more here.
Keywords: treatment; highly active; cladribine tablets; multiple sclerosis ... See more keywords
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2019.01.038
Abstract: BACKGROUND Immune reconstitution therapies (IRT) for patients with multiple sclerosis are used for short, intermittent treatment periods to induce immune resetting and allow subsequent treatment-free periods. Cladribine tablets are postulated to be an IRT that… read more here.
Keywords: treatment; year; cladribine tablets; multiple sclerosis ... See more keywords
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1717499
Abstract: Abstract Aims: To assess the cost-utility of cladribine tablets versus fingolimod in patients with highly active relapsing-remitting multiple sclerosis (RRMS) in Portugal. Methods: A 1-year cycle cohort-based Markov state transition model was developed to simulate… read more here.
Keywords: cladribine tablets; highly active; multiple sclerosis; tablets versus ... See more keywords
Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13919
Abstract: Cladribine tablets have shown significant efficacy for the treatment of relapsing multiple sclerosis, a chronic and debilitating immune‐mediated disorder. This study was conducted to examine acute and/or cumulative effects of cladribine tablets 10 mg (3.5… read more here.
Keywords: cladribine tablets; multiple sclerosis; relapsing multiple; effects cladribine ... See more keywords
Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15316
Abstract: The aim was to show the application of the prevalence estimator of Expanded Disability Status Scale (EDSS) improvement over time in patients treated with cladribine tablets in the phase III CLARITY/CLARITY extension trials. read more here.
Keywords: improvement; prevalence disability; treated cladribine; patients treated ... See more keywords